Compare Newmont Corporation (NEM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Viatris Inc — how do they compare? Newmont Corporation trades at $118.36 (market cap $123.50B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Newmont Corporation is far larger — about 6.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| NEM | VTRS | |
|---|---|---|
Market Cap | $123.50B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $17.86 |
52-Week Low | $67.38 | $9.49 |
Enterprise Value | $120.09B | $30.80B |
Dividend Yield | 0.89% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $119.12, up 1.59% with strong technical momentum as it approaches resistance near $120. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.10 versus $2.05 forecast, continuing a trend of earnings outperformance. Revenue growth accelerated to $22.67 billion in 2025 with net income margin expanding to 33.36%. Recent news highlights resolution of Nevada disputes with Barrick Mining and strong gold price environment supporting miner profitability.
Outlook remains positive with analyst consensus price target of $133 representing 11.6% upside potential. Key opportunities include continued gold price strength and operational efficiency gains, while risks involve potential cost inflation and gold price volatility. With 76% analyst buy ratings and improving cash flow trends, NEM appears well-positioned for continued growth in the current commodity cycle.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
